基于人群的美国早期 HER-2 阳性乳腺癌肿瘤患病率估计。
Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US.
机构信息
Surveillance Research Program, National Cancer Institute, Bethesda, Maryland, USA.
出版信息
Cancer Invest. 2010 Nov;28(9):963-8. doi: 10.3109/07357907.2010.496759.
Abstract
The goal of this study was to estimate prevalence of HER-2 positive tumors in a population-based sample of 1026 women diagnosed in 2005 with early stage breast cancer. We modeled the relationship between patient and tumor characteristics and HER-2. HER-2 positive estimates were 19% for women aged ≤ 49 years and 15% aged ≥ 50 years. HER-2 varied by tumor grade and size in women aged ≤ 49 years but was not significant in multivariate analysis. Tumor grade and race were associated with HER-2 for women aged ≥ 50 years after controlling for other variables. HER-2 varies by age and by race and tumor in older women.
摘要
本研究的目的是在一个 2005 年确诊为早期乳腺癌的 1026 名女性的基于人群的样本中，估计 HER-2 阳性肿瘤的患病率。我们建立了患者和肿瘤特征与 HER-2 之间的关系模型。年龄≤49 岁的女性中 HER-2 阳性的估计值为 19%，年龄≥50 岁的女性中 HER-2 阳性的估计值为 15%。在年龄≤49 岁的女性中，HER-2 随肿瘤分级和大小而变化，但在多变量分析中无统计学意义。在控制其他变量后，年龄≥50 岁的女性中，肿瘤分级和种族与 HER-2 相关。在老年女性中，HER-2 随年龄、种族和肿瘤而变化。
相似文献
1
Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US.基于人群的美国早期 HER-2 阳性乳腺癌肿瘤患病率估计。
Cancer Invest. 2010 Nov;28(9):963-8. doi: 10.3109/07357907.2010.496759.
2
Recent breast cancer trends among Asian/Pacific Islander, Hispanic, and African-American women in the US: changes by tumor subtype.美国亚裔/太平洋岛民、西班牙裔和非裔美国女性近期的乳腺癌发病趋势：按肿瘤亚型划分的变化
Breast Cancer Res. 2007;9(6):R90. doi: 10.1186/bcr1839.
3
Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States.美国不同种族和族裔间乳腺癌诊断时的分期和癌症特异性生存的差异。
JAMA. 2015 Jan 13;313(2):165-73. doi: 10.1001/jama.2014.17322.
4
StatBite Lifetime Risk of Breast Cancer Subtypes by Race.按种族划分的乳腺癌亚型终生风险简讯
J Natl Cancer Inst. 2011 Apr 6;103(7):537. doi: 10.1093/jnci/djr123. Epub 2011 Mar 23.
5
Difference in breast cancer stage, treatment, and survival.乳腺癌分期、治疗及生存率的差异。
Arch Intern Med. 2003 May 26;163(10):1241-2. doi: 10.1001/archinte.163.10.1241.
6
Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base.种族差异对乳腺癌新辅助化疗的应用和结局的影响：来自国家癌症数据库的结果。
J Clin Oncol. 2015 Dec 20;33(36):4267-76. doi: 10.1200/JCO.2015.63.7801. Epub 2015 Nov 23.
7
Race and risk of subsequent aggressive breast cancer following ductal carcinoma in situ.种族与导管原位癌（DCIS）后侵袭性乳腺癌风险的关系。
Cancer. 2019 Sep 15;125(18):3225-3233. doi: 10.1002/cncr.32200. Epub 2019 May 23.
8
Racial disparities in breast cancer diagnosis and treatment by hormone receptor and HER2 status.按激素受体和HER2状态划分的乳腺癌诊断与治疗中的种族差异。
Cancer Epidemiol Biomarkers Prev. 2015 Nov;24(11):1666-72. doi: 10.1158/1055-9965.EPI-15-0293. Epub 2015 Oct 13.
9
Differences in breast cancer stage, treatment, and survival by race and ethnicity.乳腺癌分期、治疗及生存率在种族和族裔方面的差异。
Arch Intern Med. 2003 Jan 13;163(1):49-56. doi: 10.1001/archinte.163.1.49.
10
Age-specific incidence of breast cancer subtypes: understanding the black-white crossover.乳腺癌亚型的年龄特异性发病率：理解黑-白交叉现象。
J Natl Cancer Inst. 2012 Jul 18;104(14):1094-101. doi: 10.1093/jnci/djs264. Epub 2012 Jul 5.
引用本文的文献
1
Novel anti-HER2 nanobody-drug conjugates with enhanced penetration of solid tumor and BBB, reduced systemic exposure and superior antitumor efficacy.新型抗HER2纳米抗体-药物偶联物，具有增强的实体瘤和血脑屏障穿透能力、降低的全身暴露水平以及卓越的抗肿瘤疗效。
Acta Pharmacol Sin. 2025 Aug 18. doi: 10.1038/s41401-025-01634-3.
2
FKBP10 expression and TP53 mutation predict prognosis and chemotherapy response in triple-negative breast cancer.FKBP10表达和TP53突变可预测三阴性乳腺癌的预后及化疗反应。
Discov Oncol. 2025 Jul 25;16(1):1409. doi: 10.1007/s12672-025-03275-8.
3
Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Early Breast Cancer Treatment and Outcomes by Risk of Recurrence: A Retrospective US Electronic Health Records Study.根据复发风险对人表皮生长因子受体2阳性（HER2+）早期乳腺癌进行的治疗及预后：一项美国电子健康记录回顾性研究
Cancers (Basel). 2025 May 31;17(11):1848. doi: 10.3390/cancers17111848.
4
Safety and efficacy of docosahexaenoic acid supplementation during neoadjuvant breast cancer therapy: Findings from the phase II, double-blind, randomized controlled DHA-WIN trial.新辅助乳腺癌治疗期间补充二十二碳六烯酸的安全性和有效性：II期双盲随机对照DHA-WIN试验的结果
Int J Cancer. 2025 Oct 1;157(7):1405-1419. doi: 10.1002/ijc.35517. Epub 2025 Jun 9.
5
Machine learning-based fusion model for predicting HER2 expression in breast cancer by Sonazoid-enhanced ultrasound: a multicenter study.基于机器学习的索纳造影剂增强超声预测乳腺癌HER2表达的融合模型：一项多中心研究
Front Med (Lausanne). 2025 May 21;12:1585823. doi: 10.3389/fmed.2025.1585823. eCollection 2025.
6
Evaluation of pathological complete response rates in breast cancer patients undergoing neoadjuvant therapy.接受新辅助治疗的乳腺癌患者病理完全缓解率的评估。
Rev Bras Ginecol Obstet. 2025 Apr 30;47. doi: 10.61622/rbgo/2025rbgo13. eCollection 2025.
7
T-DM1: a promising adjuvant therapy option for stage I HER2-positive breast cancer-interpreting ATEMPT trial results from a clinical perspective.T-DM1：I期HER2阳性乳腺癌有前景的辅助治疗选择——从临床角度解读ATEMPT试验结果
Gland Surg. 2025 Apr 30;14(4):785-790. doi: 10.21037/gs-2025-23. Epub 2025 Apr 25.
8
Treatment patterns and associated outcomes among patients with HER2+ metastatic breast cancer in the United States: an observational cohort study.美国HER2阳性转移性乳腺癌患者的治疗模式及相关结局：一项观察性队列研究
Oncologist. 2025 Apr 4;30(4). doi: 10.1093/oncolo/oyae280.
9
Postoperative radiotherapy improves long-term survival in HER2-positive metastatic breast cancer: real-world evidence from the latest SEER database.术后放疗可改善HER2阳性转移性乳腺癌的长期生存率：来自最新SEER数据库的真实世界证据。
Breast Cancer Res Treat. 2025 Jun;211(2):489-500. doi: 10.1007/s10549-025-07665-y. Epub 2025 Mar 14.
10
Antibody-drug conjugates in patients with advanced/metastatic HER2-low-expressing breast cancer: a systematic review and meta-analysis.晚期/转移性HER2低表达乳腺癌患者的抗体药物偶联物：一项系统评价和荟萃分析
Ther Adv Med Oncol. 2024 Nov 20;16:17588359241297079. doi: 10.1177/17588359241297079. eCollection 2024.
本文引用的文献
1
Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue repository of the Surveillance, Epidemiology, and End Results (SEER) program.人表皮生长因子受体2和雌激素受体表达，一项利用监测、流行病学和最终结果（SEER）计划的剩余组织储存库开展的示范项目。
Breast Cancer Res Treat. 2009 Jan;113(1):189-96. doi: 10.1007/s10549-008-9918-3. Epub 2008 Feb 7.
2
HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.由北中部癌症治疗组N9831组间辅助试验标本的当地、中心和参考实验室进行的HER2检测。
J Clin Oncol. 2006 Jul 1;24(19):3032-8. doi: 10.1200/JCO.2005.03.4744.
3
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.《卡罗来纳乳腺癌研究中的种族、乳腺癌亚型与生存率》
JAMA. 2006 Jun 7;295(21):2492-502. doi: 10.1001/jama.295.21.2492.
4
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.曲妥珠单抗联合辅助化疗用于可手术的HER2阳性乳腺癌
N Engl J Med. 2005 Oct 20;353(16):1673-84. doi: 10.1056/NEJMoa052122.
5
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.HER2阳性乳腺癌辅助化疗后使用曲妥珠单抗。
N Engl J Med. 2005 Oct 20;353(16):1659-72. doi: 10.1056/NEJMoa052306.
6
Race modifies the association between breast carcinoma pathologic prognostic indicators and the positive status for HER-2/neu.种族改变了乳腺癌病理预后指标与HER-2/neu阳性状态之间的关联。
Cancer. 2005 Nov 15;104(10):2189-96. doi: 10.1002/cncr.21463.
7
Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer.激素受体不能预测所有年龄组可手术乳腺癌女性的HER2/neu状态。
Ann Oncol. 2005 Nov;16(11):1755-61. doi: 10.1093/annonc/mdi364. Epub 2005 Aug 5.
8
Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer.1362例原发性可手术乳腺癌女性患者中肿瘤特征与免疫组化检测HER-2/neu之间的关联
J Clin Pathol. 2005 Jun;58(6):611-6. doi: 10.1136/jcp.2004.022772.
9
Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related.雌激素依赖性乳腺癌中HER-2/neu与孕激素受体之间的关联与年龄相关。
Breast Cancer Res Treat. 2005 May;91(1):81-7. doi: 10.1007/s10549-004-8235-8.
10
Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.激素受体阳性原发性乳腺癌中HER-2/neu与类固醇激素受体之间的定量关联
J Natl Cancer Inst. 2003 Jan 15;95(2):142-53. doi: 10.1093/jnci/95.2.142.
Zotero 插件